阿替普酶溶栓治疗急性脑梗死的临床效果

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of of thrombolysis with Ateplase in the treatment of acute cerebral infarction. Methods A total of 90 patients with acute cerebral infarction treated in our hospital from January 1, 2018 to July 1, 2019 were selected as the research object, and divided into study group and control group according to random number table method. Patients in the control group were given conventional treatment such as platelet inhibitor and free radical scavenger, while patients in the study group were treated with Alteplase thrombolysis based on the control group. The levels of inflammatory factors before and after treatment, therapeutic effects and total incidence of adverse reactions after treatment between the two groups were compared. Results There was no significant difference in the level of inflammatory factors before treatment between the two groups (P＞0.05). The levels of high sensitive C-reactive protein (hs-CRP), interleukin-1β (IL-1β) and tumor necrosis factor (TNF-α) in the two groups were lower than those before treatment, the differences were statistically significant (P＜0.05). The levels of hs-CRP, IL-1β and TNF-α in the study group were lower than those in the control group, and the differences were statistically significant (P＜0.05). The total effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05). Conclusion Thrombolysis with Ateplase can significantly reduce the level of inflammatory factors in patients with acute cerebral infarction, and improve the therapeutic effect of patients without increasing the adverse reactions of patients, which is worthy of clinical promotion and application.

Key words： Alteplase Thrombolytic therapy Acute cerebral infarction Inflammation level Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Ming-hui

Cite this article:

MA Ming-hui. Clinical effect of of thrombolysis with Ateplase in the treatment of acute cerebral infarction[J]. 中国当代医药, 2020, 27(7): 58-60.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I7/58

[1]	任毅，高小平，梁辉.阿替普酶静脉溶栓治疗急性脑梗死后发生卒中后抑郁的影响因素分析[J].国际神经病学神经外科学杂志，2018，45（3）：67-70.
[2]	孟佳雪，贺帅，谢惠芳，等.阿替普酶治疗急性脑梗死患者的出血不良反应影响因素分析[J].中国临床药理学杂志，2018，39（1）：1595-1597.
[3]	金肇权，张文彬.局部亚低温联合阿替普酶静脉溶栓对急性脑梗塞患者神经功能及日常生活能力的影响[J].中国地方病防治杂志，2017，32（11）：1273-1274.
[4]	彭琳，郭岩，王玉，等.伴有大脑中动脉高密度征的急性脑梗死静脉溶栓疗效分析[J].中华医学杂志，2017，97（3）：193-197.
[5]	黄文立，宫淑杰，吴志生，等.急性脑梗死合并前循环大血管闭塞患者桥接治疗和机械取栓临床的效果分析[J].中风与神经疾病杂志，2019，36（2）：53-55.
[6]	Park HB，Lee BK，Shin S，et al.Clinical feasibility of 3D automated coronary atherosclerotic plaque quantification algorithm on coronary computed tomography angiography：comparison with intravascular ultrasound[J].Eur J Radiol Open，2015，25（10）：3073-3083.
[7]	吴天源，罗义，吕磊，等.阿替普酶溶栓并发上肢软组织内出血致张力性水泡血泡一例[J].中华医学杂志，2017，97（19）：1515.
[8]	张玉显，张佩兰.合并脑微出血急性缺血性脑卒中患者静脉溶栓治疗的风险评估及安全性研究[J].中风与神经疾病杂志，2018，10（4）：314-316.
[9]	苏建，张津华，蒋超.阿替普酶静脉溶栓治疗急性脑梗死血管再闭塞的影响因素[J].中国老年学杂志，2019，39（4）：12-14.
[10]	朱烨，吴雅利，李宝香，等.丁苯酞联合阿替普酶对急性脑梗死患者神经功能、认知功能和Hcy 等血清学指标的影响[J].中国药房，2018，48（8）：1095-1098.
[11]	Sun Y，Xu Y，Geng L.Caspase-3 inhibitor prevents the apoptosis of brain tissue in rats with acute cerebral infarction[J].Exp Ther Med，2015，10（1）：133-138.
[12]	常虹，李雁翔，王琳.小卒中合并高血糖患者静脉溶栓的有效性和安全性[J].实用医学杂志，2017，18（20）：119-123.
[13]	Tompkins BA，Natsumeda M，Balkan W，et al.What is the future of cell-based the rapy for acute myocardial in farction[J].Circ Res，2017，120（2）：252-255.
[14]	宋程光，刘长喜，曹群，等.阿替普酶静脉溶栓治疗急性轻型缺血性脑卒中的疗效分析[J].中国医科大学学报，2019，48（2）：94-97.
[15]	马莉花，孙梦娇，原铂尧，等.替奈普酶静脉溶栓治疗急性缺血性卒中的Meta 分析[J].中国脑血管病杂志，2018，15（10）：34-42.
[16]	赵香梅，杨先芝，李法良，等.河南某医院脑梗死静脉溶栓治疗依从性分析[J].中华急诊医学杂志，2017，26（7）：784-789.